NCT01916850View on ClinicalTrials.gov

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

October 31, 2013

Conditions
Healthy
Interventions
DRUG

LX4211 400 mg

DRUG

LX4211 800 mg

DRUG

LX4211 Placebo

Trial Locations (1)

Unknown

Lexicon Investigational Site, Dallas

Sponsors
All Listed Sponsors
lead

Lexicon Pharmaceuticals

INDUSTRY